Dowdy Jackson, Chief Scientific Officer at Antigenix Therapeutics, shared a post on LinkedIn:
“I have exciting news to share! After several months of working diligently behind the scenes, I’m thrilled to announce that Antigenix Therapeutics has officially emerged from stealth. We are a biotechnology company with a mission to give cancer patients more hope and more choices. To achieve this, we are developing novel antibody-drug conjugate (ADC) therapies for cancers that are resistant to current treatments.
I’m incredibly grateful to be part of this team and excited for what the future will bring. Please check out our website (yours truly had a hand in developing it) and follow us on LinkedIn for updates.”
More posts about Antibody-Drug Conjugate.